Samina Khan
Net worth: 7 M $ as of 29/09/2023
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
J. Huff | M | 70 | 2 years | |
Michael McDonnell | M | 60 | 1 years | |
Fearghas Carruthers | M | - | 1 years | |
Michael Dambach | M | - | 1 years | |
Robin Kramer | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Manmeet Singh Soni | M | 46 | 4 years | |
Vineet R. Jindal | M | - | 5 years | |
W. Wigley | M | - | 21 years | |
James E. Bass | M | 65 | 6 years | |
Joel Proksch | M | - | 9 years | |
Shamim Ruff | F | 64 | 2 years | |
Steven Ryder | M | 73 | 1 years | |
Colin Meyer | M | 45 | 20 years | |
Christy Oliger | F | 54 | 2 years | |
Richard McGaughy | M | 52 | 19 years | |
Martin Edwards | M | 68 | 3 years | |
Jack Nielsen | M | 60 | 16 years | |
William Rose | M | 56 | 7 years | |
William McClellan | M | 64 | 6 years | |
Kevin Johnston | M | - | 2 years | |
Elaine Castellanos | F | - | 13 years | |
Rajiv Patni | M | 55 | - | |
Elizabeth Messersmith | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 2 years |
Michael Wortley | M | 76 | 8 years | |
Andrea Loewen-Rodriguez | F | 57 | 3 years | |
Dawn Bir | F | 53 | 7 years | |
Oscar Sanchez | M | - | 2 years | |
Claudia Bujold | F | - | 4 years | |
Steve Harman | M | - | 4 years | |
Edmund Doherty | M | - | 11 years | |
Masa Tanaka | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 3 years |
Dakota Gallivan | M | - | 3 years | |
Jan Reene | F | - | 3 years | |
Bhaskar Anand | M | 46 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 34 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Samina Khan
- Personal Network